User contributions
Jump to navigation
Jump to search
- 11:46, 20 May 2020 diff hist +4,434 N Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +3,645 N Section 3.2.7: PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) current
- 11:46, 20 May 2020 diff hist +3,497 N Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) current
- 11:46, 20 May 2020 diff hist +6,075 N Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +6,845 N Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +8,605 N Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +4,498 N Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +10,151 N Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +966 N Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +8,341 N Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +1,215 N Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +9,751 N Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:46, 20 May 2020 diff hist +5,417 N Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 11:45, 20 May 2020 diff hist +263 N Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5)
- 21:46, 19 May 2020 diff hist +3,630 N Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Hongjuan Cui (11th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Fei Chen (10th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Zhen Dong (9th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Xiaowen Wang (8th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Guanghui Zhang (7th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Jiayi Zhang (6th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Wen Peng (5th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Jie Xu (4th author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Gaichao Zhao (3rd author of 10.1038/s41392-020-0110-5) current
- 15:29, 19 May 2020 diff hist +77 N Pengfei Shi (2nd author of 10.1038/s41392-020-0110-5) current
- 12:16, 17 May 2020 diff hist +328 N Hemming VG., et al, Clin Diagn Lab Immunol (2001) cited as Ref 7 in DOI: 10.1080/22221751.2020.1735265 current
- 12:16, 17 May 2020 diff hist +328 N Mori I, et al, PLoS One (2008) cited as Ref 6 in DOI: 10.1080/22221751.2020.1735265 current
- 12:16, 17 May 2020 diff hist +328 N Taoran G, et al, Chin J Internal Med (2020) cited as Ref 5 in DOI: 10.1080/22221751.2020.1735265 current
- 12:16, 17 May 2020 diff hist +328 N Tai-sheng LI, et al, Chin J Lab Med (2003) cited as Ref 4 in DOI: 10.1080/22221751.2020.1735265 current
- 12:16, 17 May 2020 diff hist +328 N Li T, et al, Chin Med J (Engl) (2003) cited as Ref 3 in DOI: 10.1080/22221751.2020.1735265 current
- 12:16, 17 May 2020 diff hist +328 N World Health Organization cited as Ref 2 in DOI: 10.1080/22221751.2020.1735265 current
- 19:05, 14 May 2020 diff hist +718 N Disclosure statement (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,098 N Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,931 N Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,070 N Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +907 N Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +972 N Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +913 N Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,371 N Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,025 N Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +918 N Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +947 N Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +683 N Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +981 N Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,311 N Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265) current
- 19:05, 14 May 2020 diff hist +954 N Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,447 N Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +1,219 N Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265)
- 19:05, 14 May 2020 diff hist +785 N Section 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265)
- 19:04, 14 May 2020 diff hist +1,859 N Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265)
